Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Immunology

Abstract SY03-03: Modulating innate and adaptive immunity through the manipulation of dendritic cells

Nina Bhardwaj
Nina Bhardwaj
New York University School of Medicine, New York, NY.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1538-7445.AM10-SY03-03 Published April 2010
  • Article
  • Info & Metrics
Loading
Proceedings: AACR 101st Annual Meeting 2010; Apr 17-21, 2010; Washington, DC

Abstract

Dendritic cells (DC) are potent antigen presenting cells used in clinical trials to treat cancer and infectious diseases such as HIV. We have performed two types of clinical trials to evaluate their immunogenicity in vivo. First, we compared DC to conventional vaccine adjuvants. HLA-A2+ resected melanoma patients were enrolled into a randomized clinical trial to compare vaccines comprised of six HLA-A2-restricted peptide antigens and a foreign protein, KLH, either pulsed onto cytokine-matured, monocyte-derived DCs or emulsified in the mineral oil adjuvant Montanide ISA 51. The frequency, magnitude and quality of antigen-specific cellular immune responses in peripheral blood were found to be greater in patients receiving the Montanide vaccine. Furthermore, the primed cells were functionally superior, indicating a need to improve current DC-based vaccine approaches. Preclinical studies in mice were undertaken to evaluate the mechanism by which DC prime T cells. Contrary to previous assumptions, we found that DC vaccines have an insignificant role in directly priming CD8+ T cells, but instead function primarily as vehicles for transferring antigens to endogenous antigen presenting cells, which are responsible for the subsequent activation of T cells. This reliance on endogenous immune cells may explain the limited success of current DC vaccines to treat cancer and offers new insight into how these therapies can be improved. Future approaches will focus on creating DC vaccines that are more effective at directly priming T cells, by altering maturation factors, or abrogating the tumor induced suppression of endogenous DCs

In a second approach, we used TLR agonists targeting TLR 7, 8 and/or 9 to prime immunity to melanoma associated antigens in a series of clinical trials. They include imiquimod, resiquimod and CpG, agonists for TLR7 and/or TLR 8 and TLR9 respectively. These adjuvants when combined with the cancer testis antigen NY-ESO-1, induced integrated immune responses which were characterized by the induction of both CD4+ and CD8+ T cell immunity as well as antigen-specific antibodies in patients with resected melanoma. Strategies to optimize these various approaches to induce immunity in cancer and other chronic diseases will be discussed.

Citation Format: Nina Bhardwaj. Modulating innate and adaptive immunity through the manipulation of dendritic cells [abstract]. In: Proceedings of the AACR 101st Annual Meeting 2010; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr SY03-03

  • ©2017 American Association for Cancer Research.
Back to top
Cancer Research: 70 (8 Supplement)
April 2010
Volume 70, Issue 8 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract SY03-03: Modulating innate and adaptive immunity through the manipulation of dendritic cells
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract SY03-03: Modulating innate and adaptive immunity through the manipulation of dendritic cells
Nina Bhardwaj
Cancer Res April 15 2010 (70) (8 Supplement) SY03-03; DOI: 10.1158/1538-7445.AM10-SY03-03

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract SY03-03: Modulating innate and adaptive immunity through the manipulation of dendritic cells
Nina Bhardwaj
Cancer Res April 15 2010 (70) (8 Supplement) SY03-03; DOI: 10.1158/1538-7445.AM10-SY03-03
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Immunology

  • Abstract SY03-02: Wnt signaling generates “stem-like” self-renewing T cells that can eradicate tumors
  • Abstract SY03-01: The desirable death of the cancer cell: Immunogenic cell death for optimal chemotherapy
Show more 3

Oral Presentations - Invited Abstracts

  • Abstract SY28-04: Rational incorporation of novel agents into multimodality treatment of glioma and neuroblastoma
  • Abstract SY28-02: Connections in the BRCA1-BRCA2 pathway of homologous recombination: Implications for breast cancer development and treatment
  • Abstract SY34-04: Do we need to know what pO2 hypoxia is
Show more 3

Invited Oral Presentations - Manipulating Tumor Immunity

  • Abstract SY03-02: Wnt signaling generates “stem-like” self-renewing T cells that can eradicate tumors
  • Abstract SY03-01: The desirable death of the cancer cell: Immunogenic cell death for optimal chemotherapy
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement